{"id":"no-oac","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Aspirin","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Pentasaccharides","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Antiplatelets","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Anticoagulants","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Selective serotonin reuptake inhibitors (SSRIs)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Serotonin-norepinephrine reuptake inhibitors (SNRIs)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nonsteroidal anti-inflammatory drugs (NSAIDs)","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Thrombolytics","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet therapy","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet drugs","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet medications","action":"Avoid","effect":"Increased risk of bleeding"}],"commonSideEffects":[],"contraindications":["Mechanical heart valves (DOACs contraindicated)"],"specialPopulations":{"Pregnancy":"N-acetylcysteine (NAC) is generally considered safe for use during pregnancy, particularly when medically necessary, though data is limited and it should be used with appropriate caution. NAC crosses the placenta and may provide protective effects for both mother and fetus in cases of acetaminophen overdose. NAC is most commonly used during pregnancy for treatment of acetaminophen overdose, where early administration (within 16 hours of ingestion) has been shown to significantly improve outcomes for both mother and fetus. Common side effects of NAC include nausea, vomiting, and diarrhea, which should be monitored in pregnant patients. For pregnant women with acetaminophen overdose and potentially toxic serum levels, NAC should be administered as early as possible to prevent maternal and fetal morbidity and mortality. In cases of acute liver failure during pregnancy, NAC should be considered, especially in acetaminophen-associated cases. When using NAC during pregnancy, the benefits of treatment should be weighed against the potential risks, with consideration of the specific clinical scenario and gestational age.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"NAC may be considered as a treatment option in acute fatty liver of pregnancy with severe hepatic impairment, though there are insufficient data to make strong recommendations outside clinical centers with expertise. The American Gastroenterological Association recommends NAC for acetaminophen-associated acute liver failure (strong recommendation), which would apply to pregnant patients with this condition. Monitoring of both maternal and fetal status during NAC administration is recommended, particularly in cases of hepatic dysfunction."}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=no-oac","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:37:37.983870+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:37:44.233218+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:37:38.056019+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=no-oac","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:37:44.533179+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL194376/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:45.639743+00:00"}},"allNames":"no oac","offLabel":[],"timeline":[],"aiSummary":"5-7 sentence executive brief for pharma professionals — Eliquis (apixaban), Pfizer Inc., mechanism of action not specified, key indications include Acute Ischemic Stroke, Atrial Fibrillation or Flutter with a High Risk of Stroke, Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke, Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF, Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF, clinical differentiation not specified, commercial significance is high with $63.6B revenue, pipeline developments not specified","brandName":"No OAC","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Factor Xa","novelty":"Best-in-class","modality":"Small molecule","drugClass":"Direct Oral Anticoagulant","explanation":"","oneSentence":"","technicalDetail":"Apixaban is a selective and reversible inhibitor of Factor Xa. It has a high affinity for Factor Xa and a long half-life, which allows for once-daily dosing. Apixaban also has a low risk of bleeding and a high efficacy in preventing stroke and systemic embolism."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=no-oac","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=no-oac","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:47.293470+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Warfarin","company":"Traditional Anticoagulants","advantage":"Narrow therapeutic window, variable pharmacokinetics, and the need for regular monitoring"},{"name":"Dalteparin","company":"Traditional Anticoagulants","advantage":"Compared to Rivaroxaban in SELECT-D study, Dalteparin had a different outcome"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"no-oac","indications":{"approved":[{"name":"Acute Ischemic Stroke","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","regulator":"FDA"},{"name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07441382","phase":"NA","title":"Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-01","conditions":"Atrial Fibrillation (AF), Stroke, Hemorrhage","enrollment":200},{"nctId":"NCT07438054","phase":"","title":"PRO-AF 52: Monthly Primary-Care 12-Lead ECG Screening for Incident Atrial Fibrillation in Adults Aged ≥65 Years","status":"ENROLLING_BY_INVITATION","sponsor":"Kotyora Family Medicine Health Management and Education Association","startDate":"2026-01-01","conditions":"Atrial Fibrillation (AF)","enrollment":1000},{"nctId":"NCT05838664","phase":"","title":"A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-07-07","conditions":"Atrial Fibrillation","enrollment":2140403},{"nctId":"NCT06783868","phase":"","title":"Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control","status":"NOT_YET_RECRUITING","sponsor":"Kansas City Heart Rhythm Research Foundation","startDate":"2025-10","conditions":"Atrial Fibrillation, Stroke","enrollment":100},{"nctId":"NCT07125417","phase":"PHASE4","title":"Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure","status":"RECRUITING","sponsor":"OCEAN-SHD Study Group","startDate":"2025-05-29","conditions":"Nonvalvular Atrial Fibrillation, Aspirin, Non-Antithrombotic Therapy","enrollment":500},{"nctId":"NCT05952206","phase":"PHASE3","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","status":"RECRUITING","sponsor":"iVascular S.L.U.","startDate":"2023-10-13","conditions":"Coronary Artery Disease","enrollment":2312},{"nctId":"NCT03243175","phase":"PHASE3","title":"Avoiding Anticoagulation After IntraCerebral Haemorrhage","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2019-01-17","conditions":"Intracerebral Hemorrhage, Atrial Fibrillation, Microhaemorrhage","enrollment":300},{"nctId":"NCT06615596","phase":"EARLY_PHASE1","title":"Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-01","conditions":"Atrial Fibrillation (AF)","enrollment":3160},{"nctId":"NCT02830152","phase":"NA","title":"Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska Institutet","startDate":"2017-05-03","conditions":"Atrial Fibrillation, Stroke, Intracerebral Hemorrhage","enrollment":750},{"nctId":"NCT05204212","phase":"NA","title":"Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease","status":"RECRUITING","sponsor":"Prof. Dr. med. Ingo Eitel","startDate":"2022-03-28","conditions":"Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent","enrollment":430},{"nctId":"NCT05022758","phase":"","title":"A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-10-06","conditions":"Non-valvular Atrial Fibrillation (NVAF)","enrollment":45000},{"nctId":"NCT02067182","phase":"PHASE4","title":"Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation","status":"COMPLETED","sponsor":"Georg Nickenig","startDate":"2015-08","conditions":"Atrial Fibrillation, Cardioembolic Events, Oral Anticoagulation","enrollment":200},{"nctId":"NCT03153150","phase":"PHASE3","title":"Start or STop Anticoagulants Randomised Trial (SoSTART)","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2018-03-28","conditions":"Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive, Subarachnoid Hemorrhage","enrollment":203},{"nctId":"NCT03254147","phase":"","title":"Medical Need of OAC Reversal","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-10-15","conditions":"Atrial Fibrillation","enrollment":53969},{"nctId":"NCT01366703","phase":"","title":"Optimized Heart Failure Therapy Through Continuous Monitoring","status":"UNKNOWN","sponsor":"Kennemer Gasthuis","startDate":"2011-05","conditions":"Heart Failure","enrollment":50}],"_emaApprovals":[{"date":"","name":"No OAC","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.fiercepharma.com/pharma/while-lilly-continues-boom-q4-many-other-drugmakers-are-projecting-slide-26","date":"2026-04-07","type":"news","title":"Several drugmakers project a slide in growth as LOEs accumulate","source":"www.fiercepharma.com"},{"url":"https://www.pharmexec.com/view/novo-nordisk-2025-financial-report-2026-sales-operations-profit-outlook","date":"2026-04-07","type":"news","title":"Novo Nordisk Releases 2025 Financial Report and 2026 Sales and ...","source":"www.pharmexec.com"},{"url":"https://www.drugdiscoverytrends.com/pharma-50-2026-the-top-spot-in-pharma-rarely-lasts-lilly-is-betting-it-can-change-that/","date":"2026-04-07","type":"news","title":"Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting ...","source":"www.drugdiscoverytrends.com"},{"url":"https://www.pharmasalmanac.com/articles/pfizer-receives-fda-approval-for-remicade-biosimilar","date":"2026-04-07","type":"news","title":"Pfizer Receives FDA Approval for Remicade® Biosimilar","source":"www.pharmasalmanac.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_fda_approval_of_eucrisa_crisaborole","date":"2026-04-07","type":"news","title":"Pfizer Announces FDA Approval of EUCRISA™ (crisaborole) | Pfizer","source":"www.pfizer.com"}],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL194376","moleculeType":"Small molecule","molecularWeight":"459.36"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL194376"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":105,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"commercialAnalysis":{"text":"No OAC (no-oac) by Pfizer is a pharmaceutical product indicated for various cardiovascular conditions, including acute ischemic stroke, atrial fibrillation or flutter with a high risk of stroke, and others. As of my knowledge cutoff, the revenue data for No OAC is not specified in the provided articles.\n\nThe competitive landscape for No OAC is intense, with several pharmaceutical companies vying for market share in the cardiovascular space. According to a recent article on FiercePharma, several drugmakers, including Pfizer, are projecting a slide in growth as Loss of Exclusivity (LOE) accumulates [1]. This trend may pose a threat to No OAC's revenue trajectory.\n\nKey upcoming catalysts for No OAC include patent cliffs and label expansions. However, specific information on these events is not available in the provided articles. Additionally, pipeline competitors may emerge as a threat to No OAC's market share. According to a recent article on Drug Discovery Trends, the top spot in pharma rarely lasts, and companies like Lilly are betting on changing that [2]. This suggests a dynamic and competitive market landscape.\n\nIn terms of market outlook, the cardiovascular space is expected to continue growing, driven by an aging population and increasing prevalence of cardiovascular diseases. However, the exact market size and growth trajectory for No OAC are not specified in the provided articles. As such, I must conclude that the market outlook for No OAC is uncertain and subject to various factors, including competitive dynamics and regulatory developments.\n\nReferences:\n[1] FiercePharma, [Date]\n[2] Drug Discovery Trends, [Date]","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.fiercepharma.com/pharma/while-lilly-continues-boom-q4-many-other-drugmakers-are-projecting-slide-26","date":"","title":"Several drugmakers project a slide in growth as LOEs accumulate","source":"www.fiercepharma.com"},{"url":"https://www.pharmexec.com/view/novo-nordisk-2025-financial-report-2026-sales-operations-profit-outlook","date":"","title":"Novo Nordisk Releases 2025 Financial Report and 2026 Sales and ...","source":"www.pharmexec.com"},{"url":"https://www.drugdiscoverytrends.com/pharma-50-2026-the-top-spot-in-pharma-rarely-lasts-lilly-is-betting-it-can-change-that/","date":"","title":"Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting ...","source":"www.drugdiscoverytrends.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[{"date":"2026 Mar 26","pmid":"41889075","title":"Efficacy, Safety, and Net Clinical Benefit of Post-Atrial Fibrillation Ablation Anticoagulation.","journal":"Pacing and clinical electrophysiology : PACE"},{"date":"2026 Feb 20","pmid":"41714901","title":"Oral Anticoagulation Versus No Anticoagulation in Patients of Atrial Fibrillation With Prior History of Intracranial Hemorrhage: A Meta-Analysis.","journal":"Cardiology in review"},{"date":"2026 Jun","pmid":"41616808","title":"STrategies for antithrombotic tRreatment following transcatheter edge-to-edge repair in patients with severe mitral regurgitation: Rationale and design of STAR-TEER trial.","journal":"American heart journal"},{"date":"2026 Feb 3","pmid":"41614294","title":"Left Atrial Appendage Thrombus in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation: Prevalence and Risk Factors.","journal":"Journal of the American Heart Association"},{"date":"2026 Mar","pmid":"41352721","title":"Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis.","journal":"American journal of kidney diseases : the official journal of the National Kidney Foundation"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:47.293470+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}